Literature DB >> 15988812

Pretreatment with ursodeoxycholic acid (UDCA) as a novel pharmacological intervention in hepatobiliary scintigraphy.

Hwan Jeong Jeong1, Chang Guhn Kim.   

Abstract

The purpose of this volunteer study was to investigate whether pretreatment with UDCA before the administration of (99m)Tc DISIDA affects the biliary excretion of the DISIDA, and whether it can shorten the total imaging time. Ten young, healthy volunteers (eight males, two females, mean age: 26.3 +/- 2.1 years) participated in the study. Hepatobiliary scintigraphies were performed twice per volunteer within three days, for the control and the UDCA-pretreated studies. In the control study, the gallbladder (GB) was observed first in four cases and the intestine was observed first in another four cases; in contrast, in the UDCA challenge study, the GB was observed first in eight cases. The quantitative results for the factors related to the GB differed significantly between the control and challenge studies. When the subjects were pretreated with UDCA, the time duration until visualization of the GB was shortened, and the maximum activity of the GB became more intense. In conclusion, UDCA pretreatment before hepatobiliary scintigraphy can shorten the total imaging time for evaluating functional obstructions of the cystic duct and increase the specificity of the process.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15988812      PMCID: PMC2815817          DOI: 10.3349/ymj.2005.46.3.394

Source DB:  PubMed          Journal:  Yonsei Med J        ISSN: 0513-5796            Impact factor:   2.759


  8 in total

Review 1.  Use of ursodeoxycholic acid in patients with liver disease.

Authors:  Paul Angulo
Journal:  Curr Gastroenterol Rep       Date:  2002-02

2.  Cholescintigraphy in acute cholecystitis: use of intravenous morphine.

Authors:  D Choy; E C Shi; R G McLean; R Hoschl; I P Murray; J M Ham
Journal:  Radiology       Date:  1984-04       Impact factor: 11.105

3.  Revised estimates of diagnostic test sensitivity and specificity in suspected biliary tract disease.

Authors:  J A Shea; J A Berlin; J J Escarce; J R Clarke; B P Kinosian; M D Cabana; W W Tsai; N Horangic; P F Malet; J S Schwartz
Journal:  Arch Intern Med       Date:  1994-11-28

4.  Ursodeoxycholic acid-augmented hepatobiliary scintigraphy in the evaluation of neonatal jaundice.

Authors:  Ujjal Poddar; Anish Bhattacharya; Babu R Thapa; Bhagwant R Mittal; Kartar Singh
Journal:  J Nucl Med       Date:  2004-09       Impact factor: 10.057

Review 5.  Augmented cholescintigraphy: its role in detecting acute and chronic disorders of the hepatobiliary tree.

Authors:  D Fink-Bennett
Journal:  Semin Nucl Med       Date:  1991-04       Impact factor: 4.446

Review 6.  Therapy with ursodeoxycholic acid in cholestatic liver disease.

Authors:  P C Van de Meeberg; K J van Erpecum; G P van Berge-Henegouwen
Journal:  Scand J Gastroenterol Suppl       Date:  1993

Review 7.  Ursodeoxycholic acid therapy of chronic cholestatic conditions in adults and children.

Authors:  R Poupon; R E Poupon
Journal:  Pharmacol Ther       Date:  1995-04       Impact factor: 12.310

8.  Enhanced biliary excretion of canalicular membrane enzymes in ethynylestradiol-induced cholestasis. Effects of ursodeoxycholic acid administration.

Authors:  M Arrese; M Pizarro; N Solís; C Koenig; L Accatino
Journal:  Biochem Pharmacol       Date:  1995-10-12       Impact factor: 5.858

  8 in total
  2 in total

1.  Effect of Ursodeoxycholic Acid on the Biodistribution and Excretion of Technetium-99m Radiopharmaceuticals in Rat: A Potential Image Quality Enhancer.

Authors:  Yeon Hee Han; Hwan Jeong Jeong; Eun Mi Kim; Fatima Boud; Seok Tae Lim; Sun Young Lee; Myung Hee Sohn
Journal:  Yonsei Med J       Date:  2021-06       Impact factor: 2.759

2.  Radioactivity Reduction of 2-Deoxy-2-[18F] Fluoro-D-Glucose by Milk and Ursodeoxycholic Acid in Preclinical Study.

Authors:  Hwan-Jeong Jeong; Tarique Rajasaheb Bagalkot; Hyeon Soo Kim; Yeon-Hee Han; Minjoo Kim; Seok Tae Lim; Myung-Hee Sohn
Journal:  Nucl Med Mol Imaging       Date:  2020-02-22
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.